Linked Life Data

19414882

Source:http://linkedlifedata.com/resource/pubmed/id/19414882

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-5-5
pubmed:abstractText
The Hatch-Waxman Act of 1984 provides pharmaceutical manufacturers with an incentive to introduce reformulations of existing products that are about to lose patent protection, to extend marketing exclusivity and maintain high prices. Antidepressant reformulations are particularly common. To determine whether the use of reformulations confers benefits, we examined who uses them and whether they affect the duration of medication use. We found some evidence of benefit for subgroups of antidepressant users, although benefits varied across reformulations.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1544-5208
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
734-45
pubmed:dateRevised
2011-9-26
pubmed:meshHeading
pubmed:articleTitle
Antidepressant reformulations: who uses them, and what are the benefits?
pubmed:affiliation
Health Care Policy, Harvard Medical School in Boston, Massachusetts, USA. huskamp@hcp.med.harvard.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural